



H I G H L A N D
THERAPEUTICS

www.highlandtherapeutics.com

For Immediate Release:

HIGHLAND THERAPEUTICS TO PRESENT AT BIO CEO & INVESTOR CONFERENCE

TORONTO, Canada, January 29, 2015—Highland Therapeutics Inc. (“Highland”), a pharmaceutical company, today announced that the Company will present at the 17th Annual BIO CEO & Investor Conference at the Waldorf Astoria hotel in New York City. Highland’s presentation is scheduled for Monday, February 9, 2015 at 8:15am EST.

David Lickrish, Highland’s President and Chief Executive Officer, will provide the investment community with an overview of the Company, as well as an update on recent corporate developments, including the positive data from the Phase III study for HLD-200 (Highland’s novel formulation of methylphenidate for the treatment of Attention-Deficit/Hyperactivity Disorder, or ADHD).

A live webcast of the presentation can be accessed by visiting www.highlandtherapeutics.com. The webcast will be archived on the Company’s website for 30 days.

Hosted annually by the Biotechnology Industry Organization (BIO), the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. For more information, please visit www.bio.org.

About Highland Therapeutics Inc.

Highland Therapeutics Inc. is a specialty pharmaceutical company that, through its wholly owned subsidiary Ironshore Pharmaceuticals & Development, Inc., is leveraging its proprietary technology, DELEXIS®, to optimize the delivery of previously approved drug products. The Company’s lead product candidates, HLD-200 and HLD-100, are novel formulations of the psychostimulants (methylphenidate and amphetamine, respectively) used to treat ADHD and

are being developed to address a prevalent unmet medical need in the treatment of the disease – inadequate symptom control during the morning routine. Intended for nighttime dosing, DELEXIS® is designed to provide a consistent delay in the initial release of the active drug, followed by a period of extended release; with the objective of providing control of ADHD symptoms immediately upon waking and throughout the day.

Highland Therapeutics Inc. is a client of MaRS Discovery District's Health Venture Services group, which provides advisory services, connections to talent, customer & capital networks, and market intelligence to high-impact, Ontario-based life sciences ventures, helping them commercialize their ideas and build globally competitive companies.

For further information, please visit the Company's website at www.highlandtherapeutics.com, or contact:

Nelson F. Isabel
Chief Financial Officer
(647) 260-7875

Forward-Looking Statements

This press release contains forward-looking information, which reflects Highland's current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond Highland's control that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. These forward-looking statements are made as of the date of this press release and, except as expressly required by applicable law, Highland assumes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.